Skip Navigation

European Heart Journal 1996 17(Supplement A):8-15; doi:10.1093/eurheartj/17.suppl_A.8
Copyright © 1996 by the European Society of Cardiology.
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Urquhart, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Urquhart, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1996 1996 The European Society of Cardiology

Patient non-compliance with drug regimens: Measurement, clinical correlates, economic impact

J. Urquhart

University of Limburg, Maastricht Netherlands

Correspondence: Professor J. Urquhart, Department of Epidemiology, University of Limburg, PO Box 616, 6200 MD, Maastricht, The Netherlands

Poor compliance with rationally prescribed drug regimens attenuates benefits of treatment, making compliance a key link between process and outcome in ambulatory care. Compliance is defined as ‘the extent of correspondence between the patient's actual dosing history and the prescribed regimen’. Electronic monitoring methods reveal that >30% of patients omit many prescribed doses, irrespective of disease, prognosis, or symptoms. Some drugs are better able than others to maintain therapeutic action during the more common lapses in dosing. These are called ‘forgiving’ drugs; their duration of action is more than twice the prescribed interval between doses, allowing action to continue when one or more doses are missed. Forgiveness has limits, so long lapses in dosing will nullify action of any drug, with economic consequences that depend on the clinical consequences of lapsed action, or, with some drugs, rebound effects. These practical points have only come to light with the use of electronic monitoring of compliance, which avoids the biases created by tablet counts and other methods that make it easy for patients to censor evidence for omitted doses. All else being equal, the most forgiving drug in its class will be associated with the best outcomes, for it will be least impacted by prevalent poor and partial compliance.

Key Words: Compliance • pharmacokinetics • economics


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BMJHome page
B. Vrijens, G. Vincze, P. Kristanto, J. Urquhart, and M. Burnier
Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories
BMJ, May 17, 2008; 336(7653): 1114 - 1117.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
P. Molenaar, T. Christ, U. Ravens, and A. Kaumann
Carvedilol blocks {beta}2- more than {beta}1-adrenoceptors in human heart
Cardiovasc Res, January 1, 2006; 69(1): 128 - 139.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
M. Kindermann, C. Maack, S. Schaller, N. Finkler, K. I. Schmidt, S. Laer, H. Wuttke, H.-J. Schafers, and M. Bohm
Carvedilol but Not Metoprolol Reduces {beta}-Adrenergic Responsiveness After Complete Elimination From Plasma In Vivo
Circulation, June 29, 2004; 109(25): 3182 - 3190.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
M. L. Kukin
{beta}-Blockers in Chronic Heart Failure: Considerations for Selecting an Agent
Mayo Clin. Proc., November 1, 2002; 77(11): 1199 - 1206.
[Abstract] [PDF]

Home page
 J Am Coll CardiolHome page
C. Maack, T. Elter, G. Nickenig, K. LaRosee, M. Crivaro, A. Stablein, H. Wuttke, and M. Bohm
Prospective crossover comparison of carvedilol and metoprolol in patients with chronic heart failure
J. Am. Coll. Cardiol., October 1, 2001; 38(4): 939 - 946.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
M. Flesch, S. Ettelbruck, S. Rosenkranz, C. Maack, B. Cremers, K.-D. Schluter, O. Zolk, and M. Bohm
Differential effects of carvedilol and metoprolol on isoprenaline-induced changes in {beta}-adrenoceptor density and systolic function in rat cardiac myocytes
Cardiovasc Res, February 1, 2001; 49(2): 371 - 380.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
A. Mortara, M. T. La Rovere, G. D. Pinna, R. Maestri, S. Capomolla, and F. Cobelli
Nonselective beta-adrenergic blocking agent, carvedilol, improves arterial baroflex gain and heart rate variability in patients with stable chronic heart failure
J. Am. Coll. Cardiol., November 1, 2000; 36(5): 1612 - 1618.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
M. Bohm, S. Ettelbruck, M. Flesch, W. H van Gilst, A. Knorr, C. Maack, Y. M Pinto, M. Paul, A. C.H Teisman, and O. Zolk
{beta}-Adrenergic signal transduction following carvedilol treatment in hypertensive cardiac hypertrophy
Cardiovasc Res, October 1, 1998; 40(1): 146 - 155.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.